

**Procedura valutativa per la copertura di n. 1 posto di Professore Universitario di I fascia per il settore concorsuale 06/N1- settore scientifico disciplinare MED/46 presso il Dipartimento di Medicina Molecolare – Facoltà di Farmacia e Medicina  
Decreto Rettore Università di Roma “La Sapienza” n. 2670/2021 del 15/10/2021  
(CODICE CONCORSO 2021POR047)**

ALL. B

Decreto Rettore Università di Roma “La Sapienza” n. 2670/2021 del 15/10/2021

**PAOLA GAZZANIGA**  
**Curriculum Vitae ai fini della pubblicazione**

Roma, 26/10/2021

**Part I – General Information**

Full Name	Paola Gazzaniga

**Part II – Education**

Type	Year	Institution	Notes
University graduation	1991	Sapienza Università di Roma	Laurea in Medicina e Chirurgia 110/110 cum laude
Medical License	1992	Sapienza Università di Roma	Iscrizione ordine dei medici Nr. 43907. 07/05/1992
PhD	1992-1995	Università degli Studi di L’Aquila	Dottorato di Ricerca in Medicina Sperimentale VII ciclo
Specialty	1996-1999	Sapienza Università di Roma	Specializzazione in Oncologia (70/70 cum laude)
Post-doctoral researcher	2000-2001	Sapienza Università di Roma	Borsa post-dottorato, settore biomedico

**Part III – Appointments**

IIIA – Academic Appointments

Start	End	Institution	Position
2001	2014	Sapienza Università di Roma	Ricercatore a tempo indeterminato
2012	present	Sapienza Università di Roma	membro del Collegio dei Docenti del Dottorato di Ricerca in Medicina Molecolare
2014	present	Sapienza Università di Roma	Responsabile Unità di ricerca “Biopsia liquida dei tumori”, Dipartimento Medicina Molecolare
2015	present	Sapienza Università di Roma	Professore di II fascia SSD MED/46

IIIB – Other Appointments

Start	End	Institution	Position
-------	-----	-------------	----------

1992	1994	Deutsches Krebsforschung Zentrum (DKFZ, Heidelberg)	Visiting scientist, research program “applied tumor virology”
2013	2013	European Commission Work programme of the health of the Co-operation Programme, 7th Framework, call identifier FP7-HEALTH-2013-INNOVATION-1, area CANCER	Revisore progetti
2013	2013	Austrian Science Fundation	Revisore progetti
2014	2014	Nature Medicine	Expert Interview: liquid biopsy in non-small cell lung cancer
2014	2014	Czech Health Research Council, Ministry of Health of the Czech Republic	Revisore progetti
2014	present	British Lung Foundation	Revisore progetti
2012	present	Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR)	Revisore progetti
2016	2016	Sapienza Università di Roma	Presidente Simposio Internazionale: Liquid biopsy: tracking cancer
2016	2016	Fondazione Cassa di Risparmio di Puglia	Revisore progetti
2017	2017	Ospedale san Martino, Genova	Membro della Facoltà Masterclass, “Molecular oncology tumor board in colorectal cancer: bench to bedside to bench. The virtuous cycle of research”
2018	2018	27th TV3 Marató on Cancer	Revisore progetti
2018	2027	Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR) -ANVUR	Abilitazione scientifica Nazionale I Fascia SC 06/N1 - MED/46 (bando D.D. 1532/2016)

#### Part IV – Teaching experience

Year	Institution	Lecture/Course
2002-2003	Sapienza Università di Roma	Titolare del corso di Patologia Generale e terminologia medica, Facoltà di Farmacia (NNO)
2004-2010	Sapienza Università di Roma	Titolare del corso di Patologia Generale e terminologia medica, Facoltà di Farmacia (10 CFU)
2010-present	Sapienza Università di Roma	Titolare del corso di Patologia generale e terminologia medica (8 CFU), Corso di Laurea magistrale in Farmacia, Facoltà di Farmacia e Medicina
2011-present	Sapienza Università di Roma	Titolare del corso di Oncologia Molecolare (8 CFU), Corso di Laurea magistrale in Chimica e tecnologie farmaceutiche, Facoltà di Farmacia e Medicina
2015-2021	Sapienza Università di Roma	Titolare del corso di Patologia generale e molecolare (6 CFU), Corso di Laurea magistrale in Chimica e tecnologie farmaceutiche, Facoltà di Farmacia e Medicina
2015-present	Sapienza Università di Roma	Docente Scuola di Specializzazione in Patologia Clinica e Biochimica clinica

#### Part IV a - Other experience

2011-2014	Sapienza Università di Roma	Rappresentante Ricercatori, (Giunta di Facoltà), Facoltà di Farmacia e Medicina
2013-2014	Sapienza Università di Roma	Docente Master II livello : Professione farmacista nella nuova farmacia dei servizi
2008-2012	Sapienza Università di Roma	Membro della Commissione Didattica, Facoltà di Farmacia
2018	Sapienza Università di Roma	Docente Master II livello : Immuno-oncologia
2021	Sapienza Università di Roma	Docente Master II livello : Medicina Integrata in farmacia

#### Part V - Society memberships, Awards and Honors

Year	Title
2000	Vincitrice Progetto Giovani Ricercatori 2000 (MURST Young Researcher Program)
2014-present	Membro del Consorzio Europeo per l'analisi del valore prognostico cellule tumorali circolanti nel carcinoma mammario ( <i>Pooled analysis circulating tumor cells, EPAC-breast</i> )
2017-present	Membro del Consorzio Europeo per l'analisi del valore prognostico delle cellule tumorali circolanti nel carcinoma del polmone non a piccole cellule ( <i>Pooled analysis circulating tumor cells, Epac lung</i> )
2018-present	Membro della Commissione Scientifica presso la Società Italiana di Patologia Clinica e Medicina di Laboratorio (SipMel).
2021	Membro della Società italiana di ricerca traslazionale e Medicina di Laboratorio (Sirteps)
1998-present	Membro del comitato scientifico associazione onlus A.R.Ger.On (Associazione Ricerche geriatriche ed oncologiche)

#### Part VI - Funding Information [grants as PI-principal investigator or I-investigator]

Year	Title	Program	Grant value
2000	Meccanismi molecolari del differenziamento cellulare e dell'apoptosi indotti da alterazioni del metabolismo purinico	MURST Progetto Giovani ricercatori PI	20.000.000 (lire)
2002	Meccanismi molecolari degli effetti indotti dall'acido micofenolico in linee cellulari umane di melanoma C26A029753	Ricerca di Ateneo I	10.000
2002	effetti dell'acido micofenolico su linee cellulari umane di neuroblastoma C26F025294	Ricerca di Facoltà I	10.000
2003	effetti degli inibitori selettivi delle cox-2 in neoplasie vescicali e polmonari C26A038773	Ricerca di Ateneo I	10.000
2003	effetti dell'acido micofenolico su linee cellulari umane di melanoma C26F035094	Ricerche di Facoltà I	10.000
2004	patogenesi delle manifestazioni neurologiche della sindrome di lesch-nyhan C26F049827	Ricerca di Facoltà I	10.000
2004	effetti degli inibitori selettivi delle cox-2 in neoplasie vescicali C26A043842	Ricerca di Ateneo I	10.000
2005	Modulazione genica mediata da inibitori	Ricerca di facoltà I	10.000

	selettivi e non delle COX-2 in linee cellulari umane C26F053098		
2005	caratterizzazione delle cellule staminali cardiache C26A051918	Ricerca di Ateneo I	12000
2006	Espressione, regolazione e ruolo delle neuropiline nel carcinoma del colon-retto C26F06RX3H	Ricerca di facoltà PI	5370
2007	Effetti antitumorali di sostanze organiche di origine vegetale estratte da specie del genere Vinca e Hypoxis C26A07JT4R	Ricerche UNIVERSITARIE (ex ricerche di ATENEO) I	10.000
2007	Effetti degli antinfiammatori non steroidei nella risposta alla terapia antiblastica C26F07ZW8K	Ricerche di ATENEO FEDERATO (ex ricerche di FACOLTÀ) I	8000
2008	Profilo di chemiosensibilità delle cellule tumorali circolanti e risposta alla chemioterapia in pazienti con neoplasie solide C26F0852WR	Ricerche di ATENEO FEDERATO (ex ricerche di FACOLTÀ) I	10.000
2009	Profilo di chemiosensibilità delle cellule tumorali circolanti: valore prognostico e predittivo di risposta alla chemioterapia" C26A09LB5J	Progetto di Ricerca Università PI	10.000
2009	saggio di chemiosensibilita' in neoplasie non muscolo invasive della vescica e risposta alla chemio/immunoterapia endovescicale C26F09LMXM	Ricerche di ATENEO FEDERATO di Scienze delle Politiche Pubbliche e Sanitarie SPPS, I	10.000
2010	Rilevanza clinica della conta e della caratterizzazione molecolare delle cellule tumorali circolanti nel carcinoma della mammella: implicazioni per l'individualizzazione delle terapie. C26A10ZLW7	Ricerca universitaria PI	31500
2012	Targeting circulating tumor cells undergoing epithelial mesenchymal transition in triple negative breast cancer C26A12YHEF	Ricerca Universitaria PI	31.000
2013	circulating tumor cells in non muscle invasive bladder cancer C26A135AXH	Ricerca Universitaria PI	12.000
2015	Epithelial to mesenchymal transition (EMT) dynamics in circulating tumor cells clusters C26A15HKTF	Ricerca universitaria PI	10.000
2016	Liquid biopsy to detect PD-L1 expression in breast cancers with BRCA 1 and 2 germline mutations RM116154C3A9A19D	Progetto di Ateneo PI	31.600
2017	Development of a ctDNA liquid biopsy approach integrated in the management of patients with non-small cell lung carcinoma (NSCLC), gastrointestinal stromal tumor (GIST), colorectal carcinoma (CRC) and melanoma RG11715C7D8D18DB	Progetto di Ateneo I	29.000
2018	Urinary mutant DNA (mutDNA) as non-invasive biomarker in non-muscle invasive bladder cancer (NMIBC) RM11816421DB3FF4	Progetto di Ateneo PI	10.000
2018	Liquid biopsy to monitor Kras clonal evolution in colorectal cancer	Studio osservazionale PI (contributo Amgen)	20.000
2019	Profile of EpCAM negative circulating tumor cells: gold in the waste	Progetto di Ateneo PI	10.000

	RM11916B31436754		
2019	Multicenter prospective single-arm study investigating the efficacy and safety of second-line cetuximab plus chemotherapy treatment in initially RAS-mt mCRC patients who converted to RAS-wt at the time of first progression (co-PI)	Trial clinico fase 2 co-PI (contributo Merck Serono)	150.000
2020	Radiation Oncology and Precision Medicine: fingerprint of circulating tumor cells surviving immunogenic cell death RM120172936DC4D5	Progetto di Ateneo PI	10.000

**Part VII. Organization and participation to national/international conferences (invited speaker last 10 yrs)**

1. International conference Advances in Circulating Tumour Cells (ACTC) from Basic Research to Clinical Practice (Athens, 28/09/2012)
2. Convegno Nazionale "Highlights and emerging topics in senology and gynecologic oncology"(Roma,25/05/2012)
3. Simposio "Meet the professor, Stato dell'arte della gestione del tumore della mammella" (Roma, 18/10/2013)
4. Laboratory medicine: are we ready for a clinical governance in personalized medicine?" (Roma, 10/04/2014)
5. International conference "Updating on circulating tumor cells in cancer patients management" (Padova, 22/09/2014)
6. Convegno nazionale "Biopsia liquida: la firma dei tumori nei fluidi biologici"(Milano, 06/04/2016)
7. President International conference "Liquid biopsy: tracking cancer"(Roma 30/04/2016)
8. Corso di formazione: Highlights in oncologia, ruolo della medicina di laboratorio. Roma, 01/12/2016
9. International symposium "Resolving Cancer Heterogeneity: The way to personalized medicine (Verona, 30/06/2016)
10. Corso di aggiornamento "Carcinoma del colon-retto: opinion leaders a confronto" (Grottaferrata, 30/09/2016)
11. 48° Congresso Nazionale SIBioC – Medicina di Laboratorio (Torino, 18/10/2016)La centralità del Paziente tra Laboratorio e Clinica
12. Corso ECM: Dalle evidenze di laboratorio alla pratica clinica : e' possibile un algoritmo terapeutico nel tumore della prostata resistente alla castrazione? (Roma, 27/10/2016)
13. Il tempo dell'Immunoterapia nel trattamento dei tumori renali - Stato dell'arte e prospettive future della pratica clinica (Roma, 30/11/2016)
14. Convegno internazionale 7th SIAPEC Conference (Genova, 26/11/2016)
15. SIMeP Winter School (Roma 02/12/2016)
16. European Society Medical oncology (ESMO) (Madrid, 09/09/2017)
17. Educational course: Medicina di precisione e oncologia traslazionale (Roma, 13/09/2018)
18. Italian association medical oncology (AIOM) conference: "The best of the year meets the first post ESMO" (Roma, 06/10/2017)
19. Masterclass "Molecular oncology tumor board in colorectal cancer: bench to bedside to bench. The virtuous cycle of research (Genova, 14/10/2017)
20. "Oncology spring meeting" (Evora, 14/04/2018)
21. Convegno Nazionale SipMel. La biopsia liquida nella diagnostica oncologica. Napoli, 11/05/2018
22. International symposium on minimal residual disease in cancer (ISMRC) (Montpellier, 02/05/2018)
23. Masterclass, "Colorectal cancer". (Baveno, 11/05/2018)
24. Convegno: Una riflessione traslazionale sul carcinoma del colon-retto. Roma, 27/09/2017
25. Educational course: Targeted therapy (Roma, 11/10/2018)
26. IV congresso Nazionale SipMEL (Catania 23/10/ 2018)
27. EGFR National Symposium (Porto 25/01/ 2019).
28. Corso ECM: Terapie target ed immunoterapie nelle neoplasie polmonari avanzate (Roma, 26/02/2019)

29. Evento ECM. La medicina di precisione: personalizzata, preventiva, predittiva, partecipativa. Roma, 12/6/2019
30. Corso di aggiornamento: "L'approccio multidisciplinare nel carcinoma della prostata: prassi e innovazione (Roma, 15/11/2019)
31. Convegno nazionale SipMEL. (Riva del Garda, 9/10/ 2019)
32. International Webinar. Current Status and Future Perspectives of ctDNA-Based Liquid Biopsy in Cancer (10/07/2020)
33. Grandangolo 2020 E-Seminar - Medicina di precisione" 11 dicembre 2020

## Part VIII – Research Activities and collaborations

Keywords

Brief Description

Liquid biopsy	<p>Prof. Gazzaniga started her career in oncological research applying at the study of viral cancers. During her PhD training, she attended the laboratory of viral oncology at Deutesches Krebsforschungszentrum, directed by Prof. Harald zur Hausen. Back to Italy she started working on cancer biomarkers in blood samples. Before the era of liquid biopsy, she demonstrated the impact of circulating biomarkers in patients with bladder tumors. When the promise of liquid biopsy became a more solid clinical perspective, she equipped her laboratory with different instruments for circulating tumor cells and ctDNA isolation and became involved in several studies aimed to clarify the clinical utility of liquid biopsies. She leads a highly motivated group dedicated to the translation of major achievements in the field of liquid biopsy into concrete tools for cancer patients management. She is involved in the study of the mechanisms underlying the clonal evolution of solid tumors through liquid biopsies, with the following aims: 1) identification of predictive biomarkers of response to targeted therapies and immunotherapies 2) early identification of the onset of drug resistance 3) identification of new therapeutic targets. Through national and international collaborations, she is involved in several pilot and phase 2 studies aimed to definitely integrate liquid biopsies into clinical practice.</p> <p>Main research focuses:</p> <p>1991-1994: Diagnostic of Human papillomavirus infection in bladder cancer specimens</p> <p>1995-2000: Biomarkers of progression in solid tumors, with specific focus on apoptotic machinery defects</p> <p>2000-2008: Biomarkers of drug resistance in tumor tissues and peripheral blood samples from cancer patients</p> <p>2008-present: Advanced diagnostic of solid tumors through liquid biopsy. Advanced liquid biopsy technologies for circulating tumor cells isolation. Advanced liquid biopsy technologies for circulating tumor DNA isolation (size-based methods and antigen-dependent methods). Advanced liquid biopsy technologies for circulating tumor cells molecular characterization for predictive purpose. Advanced liquid biopsy technologies for circulating tumor DNA sequencing for diagnostic and therapeutic purposes.</p> <p><b>International collaborations:</b> Institute of Tumour Biology at the University Medical Centre Hamburg-Eppendorf (Klaus Pantel); Institut Curie &amp; UVSQ/Université Paris-Saclay (François-Clément Bidard); Division of Molecular &amp; Clinical Cancer Sciences, University of Manchester (Colin Lindsay); Robert H Lurie Comprehensive Cancer Center, Northwestern University (Massimo Cristofanilli); AdnaGen AG, Langenhagen (Sigfrid Hauch)</p> <p><b>National collaborations:</b> Istituto Oncologico Veneto (Rita Zamarchi); Istituto Superiore di Sanità (Ann Zeuner); Università degli studi di Torino (Federica di Nicolantonio); Università Campus Biomedico (Bruno Vincenzi); Università Cattolica del Sacro Cuore (Ettore Capoluongo); Università degli Studi di Roma "Foro Italico"(Guido Carpino), IRCCS San Martino IST (Alberto Sobrero)</p>
Circulating tumor cells	
Circulating tumor DNA	
Cancer biomarker	
Precision oncology	
Molecular assays	
Mutation analysis	
Liquid biopsy assay validation	

L'attività di ricerca della Prof.ssa Gazzaniga è principalmente incentrata alla diagnostica molecolare avanzata dei tumori solidi attraverso l'uso di biopsie liquide (analisi del DNA tumorale circolante e di cellule tumorali circolanti isolati da plasma e da urine), con i seguenti obiettivi: 1) identificazione di biomarcatori predittivi di risposta a terapie a bersaglio molecolare ed immunoterapie 2) identificazione precoce dell'insorgenza di farmacoresistenza 3) identificazione di nuovi bersagli terapeutici. Attraverso collaborazioni nazionali e internazionali, è coinvolta in numerosi studi pilota e di fase 2 volti a integrare definitivamente la biopsia liquida dei tumori nella pratica clinica
Principali interessi di ricerca
1991-1994: Analisi della presenza di trascritti virali (Papillomavirus umani) in neoplasie della vescica
1995-2000: Biomarcatori prognostici nei tumori uroteliali e nei melanomi metastatici con particolare riferimento alla morte cellulare programmata
2000-2008: Analisi di biomarcatori di farmacoresistenza su campioni di tessuto e sangue di pazienti con neoplasie solide
2008-oggi: Diagnostica molecolare dei tumori attraverso biopsia liquida. Analisi di biomarcatori prognostici e predittivi su sangue periferico di pazienti con neoplasie solide. Ottimizzazione di protocolli di isolamento ed analisi molecolare di cellule tumorali circolanti. Ottimizzazione di protocolli di analisi genomica del DNA tumorale circolante isolato da plasma e da urine di pazienti con tumori solidi.
<b>Principali collaborazioni internazionali:</b> Institute of Tumour Biology at the University Medical Centre Hamburg-Eppendorf (Klaus Pantel); Institut Curie & UVSQ/Université Paris-Saclay (François-Clément Bidard); Division of Molecular & Clinical Cancer Sciences, University of Manchester (Colin Lindsay); Robert H Lurie Comprehensive Cancer Center, Northwestern University (Massimo Cristofanilli); AdnaGen AG, Langenhagen (Sigfrid Hauch); Université de Montpellier (Catherine Alix-Panabieres)
<b>Principali collaborazioni Nazionali:</b> Istituto Oncologico Veneto (Rita Zamarchi); Istituto Superiore di Sanità (Ann Zeuner); Università degli studi di Torino (Federica di Nicolantonio); Università Campus Biomedico (Bruno Vincenzi); Università Cattolica del Sacro Cuore (Ettore Capoluongo); Università degli Studi di Roma "Foro Italico"(Guido Carpino), IRCCS San Martino IST (Alberto Sobrero); IRCCS CRO Aviano National Cancer Institute (Lorenzo Gerratana)

#### Part IX. Direction or participation in editorial committees of scientific journals

2009	present	Lancet Oncology, Cancer Research; Clinical Cancer Research, Scientific Reports ; Annals of Oncology; International Journal of Cancer; Oncotarget; Molecular Oncology; British Journal of Cancer; BJU Int; Cancer Cell Int; Breast Cancer Research and treatment; Current Cancer Drug Target; Breast Cancer Res.	Reviewer
2010	2011	Current Cancer Drug Targets	Guest Editor: <i>Cancer Therapy: Are we Missing the target?</i>
2013	present	Chinese. J Cancer Res	Editorial board member
2013	present	J. Tum	Editorial board member
2019	present	Disease Markers	Editor in Chief
2019	Present	Diagnostics	Editorial Board member
2021	present	Annals Genetics	Editorial board member

2019	2020	Cancers	Guest Editor: <i>CTCs heterogeneity and precision oncology</i>
2021	Present	Frontiers in Oncology	Guest editor: <i>Identifying Achilles heel in RAS-driven cancers</i>
2021	present	Diagnostics	Guest Editor: <i>Liquid biopsy and precision oncology</i>

### Part X – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	100	Pubmed, Scopus	1994	2021
Papers [national]	2	Google Scholar	1995	1997
Books [scientific]	2	Google Scholar	1995	2004

Total Impact factor (calculated on the publication years)	461,3 (inCites)	
Average Impact factor per Product*	4,6	
Impact factor last 5 years	133.9 (inCites)	
Average Impact factor per Product* (last 5 yrs)	5.8	
Impact factor last 10 years	241,37 (inCites)	
Total Citations	3172 (Scopus)	Parametri Commissario 06/N1
Average Citations per Product	31,7	43
Hirsch (H) index	30 (Scopus)	2040
Normalized H index**	1	23

\*Impact factor relative to the publication year, \*\*H index divided by the academic seniority.

### Part XI– Selected Publications

#### Within the 16 selected publications:

Total IF: 119.4 (*Reported IF is from the year of publication*)

Total citations: 1513

First/Last author: 13

11 publications with IF>5 (8 first/last name)

1.Nicolazzo C, Barault L, Caponnetto S, De Renzi G, Belardinilli F, Bottillo I, Bargiacchi S, Macagno M, Grammatico P, Giannini G, Cortesi E, Di Nicolantonio F, **Gazzaniga P.** \* (\*Corresponding author). *True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature.* **Cancer Letters**, 2021 Jun 1; 507:89-96. doi: 10.1016/j.canlet.2021.03.014. Epub 2021 Mar 18.PMID: 33744389

IF 2021: 8.6

Citations (From Scopus): 1



2. Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, **Gazzaniga P**, Manso L, Zamarchi R, Antelo ML, De Mattos-Arruda L, Generali D, Caldas C, Munzone E, Dirix L, Delson AL, Burstein H, Qadir M, Ma C, Scott JH, Bidard FC, Park JW, Rugo HS. *Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy*. **J Natl Cancer Inst.** **2021** Apr 6;113(4):443-452. doi: 10.1093/jnci/djaa113. PMID: 3277024

IF 2021: 13.5

Citations (From Scopus): 4

3. Chiara Nicolazzo, Ludovic Barault, Salvatore Caponnetto, Marco Macagno, Gianluigi de Renzi, Angela Gradilone, Francesca Belardinilli, Enrico Cortesi, Federica Di Nicolantonio, **Paola Gazzaniga\*** (\*Corresponding author) *Circulating methylated DNA to monitor the dynamics of RAS mutation clearance in plasma from metastatic colorectal cancer patients*. **Cancers**, **2020**, Dec 4;12(12):3633. doi: 10.3390/cancers12123633. PMID: 33291569

IF 2020: 6.6

Citations (From Scopus): 2

4. Nicolazzo C, Raimondi C, Gradilone A, Emiliani A, Zeuner A, Francescangeli F, Belardinilli F, Seminara P, Loreni F, Magri V, Tomao S, **Gazzaniga P.** \* (\*Corresponding author) *Circulating Tumor Cells in Right- and Left-Sided Colorectal Cancer*. **Cancers**, **2019** Jul 24;11(8). pii: E1042. doi: 10.3390/cancers11081042 PMID: 31344798

IF 2019: 6.1

Citations (From Scopus): 9

5. Lindsay CR, Blackhall F, Carmel A, Fernandez-Gutierrez F, **Gazzaniga P**, Groen H, Hilterman TJN, Muinelo-Romay L, Pantel K, Rossi E, Terstappen L, Wikman H, Soria J-C, Farace F, Renehan A, Dive C, Besse B, Michiels S. *EPAC-Lung: Pooled Analysis of Circulating Tumor Cells in Advanced Non-Small Cell Lung Cancer*. **Eur. J Cancer**, **2019** Jun 26;117:60-68. doi: 10.1016/j.ejca.2019.04.01 PMID: 31254940

IF 2019: 7.27

Citations (From Scopus): 30

6. Raimondi C, Nicolazzo C, Belardinilli F, Loreni F, Gradilone A, Mahdavian Y, Gelibter A, Giannini G, Cortesi E, **Gazzaniga P.** \* (\*Corresponding author). *Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer*. **Cancers**, **2019** . Jan 4;11(1). pii: E42. doi: 10.3390/cancers11010042. PMID: 30621206

IF 2019: 6.1

Citations (From Scopus): 18

7. Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, Gandini O, Mastromartino M, Del Bene G, Prete A, Longo F, Cortesi E, **Gazzaniga P.** \* (\*Corresponding author). *Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab*. **Sci Rep.** **2016** Aug 24;6:31726. doi: 10.1038/srep31726. PMID: 2755317

IF 2016: 4.25

Citations (From Scopus): 149

8. **Gazzaniga P\*** (\*Corresponding author), de Berardinis E, Raimondi C, Gradilone A, Busetto GM, De Falco E, Nicolazzo C, Giovannone R, Gentile V, Cortesi E, Pantel K. *Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer*. **Int J Cancer**, **2014**. Oct 15;135(8):1978-82. 10.1002/ijc.28830. PMID: 24599551

IF 2014: 5.7

Citations (From Scopus): 72

9. Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, **Gazzaniga P**, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S. *Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data*. **Lancet Oncol.** 2014 Apr;15(4):406-14. PMID: 24636208

IF 2014: 24.7

Citations (From Scopus): 506

10. **Gazzaniga P**, \* (\*Corresponding author), Gradilone A, de Berardinis E, Busetto GM, Raimondi C, Gandini O, Nicolazzo C, Petracca A, Vincenzi B, Farcomeni A, Gentile V, Cortesi E, Frati L. *Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis*. **Ann Oncol.** 2012; 23(9):2352-6. PMID: 22351740

IF 2012: 7.3

Citations (From Scopus): 75

11. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F, Cortesi E, **Gazzaniga P**. *Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients*. *Breast Cancer Res Treat.* 2011 Nov;130(2):449-55. PMID: 21298334

IF 2011: 4.9

Citations (From Scopus): 205

PRESS/MEDIA RELEASE <https://www.dottnet.it/articolo/8874/Tumore-al-seno-nelle-breast-unit-in-40-giorni-dal-dubbio-alla-cura>

12. A. Gradilone, G. Naso., C. Raimondi, E. Cortesi, O. Gandini, B. Vincenzi, R. Saltarelli, E. Chiapparino, F. Spremberg, M. Cristofanilli, L. Frati, A.M. Aglianò, and **P. Gazzaniga\*** (\*Corresponding author). *Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): Prognosis, drug resistance and phenotypic characterization*. **Annals Oncol**, 2011 Jan;22(1):86-92 PMID: 20603432

IF 2011: 6.4

Citations (From Scopus): 95

13. **Gazzaniga P**, \* (\*Corresponding author), Naso G, Gradilone A, Cortesi E, Gandini O, Gianni W, Fabbri MA, Vincenzi B, di Silverio F, Frati L, Aglianò AM, Cristofanilli M. *Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors*. **Int J Cancer**, 2010 May 15;126(10):2437-47. PMID: 19821489

IF 2010: 4.9

Citations (From Scopus):42

PRESS/MEDIA RELEASE, Università : le eccellenze romane <https://www.pressreader.com/italy/corriere-della-sera-roma/20100926/281629596610174>

PRESS/MEDIA RELEASE, <http://www.andosonlusnazionale.it/news/2009/06/seno-a-caccia-delle-cellule-circolanti.html>

PRESS/MEDIA RELEASE <https://www.italiasalute.it/2623/pag2/Nuovo-approccio-terapeutico-per-cancro-al-seno.html>

PRESS/MEDIA RELEASE <https://www.iltamtam.it/2010/09/11/metastasi-in-circolazione-un-esame-del-sangue-le-scopre/?cn-reloaded=1>

PRESS/MEDIA RELEASE [https://www.corriere.it/salute/09\\_giugno\\_26/tumore\\_seno\\_cellule\\_circolanti\\_62fd9854-6239-11de-8ba1-00144f02aabc.shtml](https://www.corriere.it/salute/09_giugno_26/tumore_seno_cellule_circolanti_62fd9854-6239-11de-8ba1-00144f02aabc.shtml)

PRESS/MEDIA RELEASE <https://www.tio.ch/people/people/470501/tumori-esperti-italiani-colpire-cellule-circolanti-per-vincere-cancro>

PRESS/MEDIA RELEASE <https://www.campus.rieti.it/notizie/attualita/362-per-curare-i-tumori-prima-e-meglio-caccia-alle-cellule-circolanti>

PRESS/MEDIA RELEASE <https://www.liquidarea.com/2009/06/nuovo-approccio-per-la-terapia-anti-cancro-togliere-dalla-circolazione-sanguigna-le-cellule-tumorali/>

14. **P. Gazzaniga\*** (\*Corresponding author), A. Gradilone, A. Petracca, C. Nicolazzo, C. Raimondi, R. Iacovelli, G. Naso, E. Cortesi. *Molecular markers in circulating tumor cells from metastatic colorectal cancer patients* **J Cell Mol Med** 2010. Aug;14(8):2073-7. PMID: 20597995

IF 2001: 4.6

Citations (From Scopus):63

15. **Gazzaniga P.**, Gradilone A., Giuliani L., Gandini O., Silvestri I., Nofroni I., Sacconi G., Frati L, Agliano'A. M. *Expression and prognostic significance of livin, survivin and other apoptosis related genes in the progression of superficial bladder cancer.* **Annals Oncol.**, 2003 Jan;14(1):85-90 PMID: 12488298

IF 2003: 3.6

Citations (From Scopus): 186

16. **Gazzaniga P.**, Gandini O., Giuliani L., Magnanti M., Gradilone A., Silvestri I., Gianni W., Gallucci M., Frati L. and Agliano' A. M. *Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients.* **Clin. Cancer Res.**, 2001, 7; 577-583. PMID: 11297251

IF 2001: 5

Citations (From Scopus): 56

## Part XII– All Publications (n. 100)

First/Last author: n. 65

1. Nicolazzo C, Barault L, Caponnetto S, De Renzi G, Belardinilli F, Bottillo I, Bargiacchi S, Macagno M, Grammatico P, Giannini G, Cortesi E, Di Nicolantonio F, **Gazzaniga P.** *True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature.* **Cancer Letters**, 2021 Jun 1; 507:89-96. doi: 10.1016/j.canlet.2021.03.014. Epub 2021 Mar 18. PMID: 33744389 IF 8.6

2. Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, **Gazzaniga P**, Manso L, Zamarchi R, Antelo ML, De Mattos-Arruda L, Generali D, Caldas C, Munzone E, Dirix L, Delson AL, Burstein H, Qadir M, Ma C, Scott JH, Bidard FC, Park JW, Rugo HS. *Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy.* **J Natl Cancer Inst.** 2021 Apr 6;113(4):443-452. doi: 10.1093/jnci/djaa113. PMID: 32770247; PMCID: PMC8023821. IF 13.5

3. Chiara Nicolazzo, Ludovic Barault, Salvatore Caponnetto, Marco Macagno, Gianluigi de Renzi, Angela Gradilone, Francesca Belardinilli, Enrico Cortesi, Federica Di Nicolantonio, **Paola Gazzaniga** . *Circulating methylated DNA to monitor the dynamics of RAS mutation clearance in plasma from metastatic colorectal cancer patients.* **Cancers**, 2020, Dec 4;12(12):3633. doi: 10.3390/cancers12123633. PMID: 33291569 IF. 6.4

4. Nicolazzo C, Loreni F, Caponnetto S, Magri V, Vestri AR, Zamarchi R, Gradilone A, Facchinetti A, Rossi E, Cortesi E, **Gazzaniga P.** *Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer.* **Oncotarget.** 2020 Nov 10;11(45):4115-4122. PMID: 3322709. IF 3.3

5. **Paola Gazzaniga** , Chiara Nicolazzo , Salvatore Caponnetto , Enrico Cortesi *About RAS mutation Clearance in Plasma ctDNA from RAS- mutant colorectal cancer patients.* JCO Precision Oncology 2021, 5: 389-390 IF 4.8
6. De Renzi G, Gaballo G, **Gazzaniga P**, Nicolazzo C. *Molecular Biomarkers according to Primary Tumor Location in Colorectal Cancer: Current Standard and New Insights.* Oncology. 2021 Oct 30;1-9. doi: 10.1159/000510944 PMID: 33130682. IF 2.6
7. Nicolazzo C, de Berardinis E, **Gazzaniga P**. *Liquid Biopsy for Predicting Bacillus Calmette-Guérin Unresponsiveness in Non-muscle-invasive Bladder Cancer.* Eur Urol Oncol. 2021 Feb;4(1):124-125. doi: 10.1016/j.euo.2020.09.003. Epub 2020 Oct 2. PMID: 33012667 Forecast IF 6.3
8. Nicolazzo C, Raimondi C, Gradilone A, Emiliani A, Zeuner A, Francescangeli F, Belardinilli F, Seminara P, Loreni F, Magri V, Tomao S, **Gazzaniga P**. *Circulating Tumor Cells in Right- and Left-Sided Colorectal Cancer.* Cancers (Basel). Cancers, 2019 Jul 24;11(8). pii: E1042. doi: 10.3390/cancers11081042 PMID: 31344798 IF 6.4
9. Nicolazzo C, Gradilone A, **Gazzaniga P**. *Improving the Nuclear-Localized Androgen Receptor Splice Variant 7 Test.* JAMA Oncol. 2019 Mar 1;5(3):433-434. doi: 10.1001/jamaoncol.2018.6683. PMID: 30703189. IF 24.7
10. Nicolazzo C, Gradilone A, Loreni F, Raimondi C, **Gazzaniga P**. *EpCAM low Circulating Tumor Cells: Gold in the Waste.* Dis Markers. 2019 Sep 17;2019:1718920. doi: 10.1155/2019/1718920 PMID: 31636732 IF 3
11. Lindsay CR, Blackhall F, Carmel A, Fernandez-Gutierrez F, **Gazzaniga P**, Groen H, Hilterman TJN, Muinelo-Romay L , Pantel K, Rossi E, Terstappen L, Wikman H, Soria J-C, Farace F, Renehan A, Dive C, Besse B, Michiels S. *EPAC-Lung: Pooled Analysis of Circulating Tumor Cells in Advanced Non-Small Cell Lung Cancer.* Eur. J cancer, 2019 Jun 26;117:60-68. doi: 10.1016/j.ejca.2019. PMID: 31254940 IF 7.27
12. Massimo Cristofanilli , Jean-Yves Pierga , James Reuben , Alfred Rademaker , Andrew A. Davis , Dieter J. Peeters , Tanja Fehm , Franco Nolé , Rafael Gisbert-Criado , Dimitrios Mavroudis , Salvatore Grisanti , Mario Giuliano , Jose A. Garcia-Saenz , Justin Stebbing , Carlos Caldas , **Paola Gazzaniga** , Luis Manso , Rita Zamarchi , Angela Fernandez de Lascoiti , Leticia De Mattos-Arruda , Michail Ignatiadis , Luc Cabel , Steven J. van Laere Franziska Meier-Stiegen , Maria-Teresa Sandri , Jose Vidal-Martinez , Eleni Politaki Francesca Consoli , Daniele Generali , Maria Rosa Cappelletti , Eduardo Diaz-Rubio , Jonathan Krell , Sarah-Jane Dawson ,Cristina Raimondi , Annemie Rutten , , Wolfgang Janni , Elisabetta Munzone , Vicente Carañana A, Sofia Agelaki ,Camillo Almici , Luc Dirix Erich-Franz Solomayer , Laura Zorzino , Lauren Darrigues , Jorge S. Reis-Filho C, Lorenzo Gerratana , Stefan Michiels , François-Clément Bidard , Klaus Pantel *The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper* Critical Reviews in Oncology/Hematology 134, 39-45, 2019 PMID: 30771872 IF 5.8
13. Raimondi C, Nicolazzo C, Belardinilli F, Loreni F, Gradilone A, Mahdavian Y, Gelibter A, Giannini G, Cortesi E, **Gazzaniga P**. *Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer.* Cancers (Basel). Jan 4;11(1), 2019 pii: E42. doi: 10.3390/cancers11010042. PMID: 30621206 IF: 6.4
14. Nicolazzo C, Belardinilli F, Caponnetto S., Gradilone A, Cortesi E., Giannini G., **Gazzaniga P**. *Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer.* Frontiers in Oncology Volume 9, 2019 doi: 10.3389/fonc.2019.01414 IF.4.8
15. Nicolazzo C, Gradilone A, Carpino G, **Gazzaniga P\***, Raimondi C\*. *Molecular Characterization of Circulating Tumor Cells to Study Cancer Immuno-evasion.* Methods Mol Biol 2019.;1884:247-258. doi: 10.1007/978-1-4939-8885-3\_17 PMID: 30465208 IF 1.2 (\*: co-senior authors)
16. Nicolazzo C, Busetto GM, Gradilone A, Sperduti I, Del Giudice F, Loreni F, Cortesi E, de Berardinis E, **Gazzaniga P\***, Raimondi C\*. *Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial.* Oncologist. 2019 May;24(5):612-616. doi: 10.1634/theoncologist.2018-0784. Epub 2019 Apr 3. PMID: 30944184; PMCID: PMC6516110. IF. 5 (\*: co-senior authors)
17. **Gazzaniga P**, Raimondi C, Urbano F, Cortesi E. *EGFR Inhibitor as Second-Line Therapy in a Patient With Mutant RAS Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment.* J. Clin. Oncol. Precision Oncology 2018, DOI: 10.1200/PO.17.00277 IF 3.3

18. Nicolazzo C, Colangelo L, Corsi A, Carpino G, Gradilone A, Sonato C, Raimondi C, Gaudio E, **Gazzaniga P**, Gianni W *Liquid Biopsy in Rare Cancers: Lessons from Hemangiopericytoma*. *Anal Cell Pathol (Amst)*. 2018 Mar 7;2018:9718585. doi: 10.1155/2018/9718585. eCollection 2018. PMID: 29707475 IF 2.1
19. Nicolazzo C, Busetto GM, Del Giudice F, Sperduti I, Giannarelli D, Gradilone A, **Gazzaniga P**, de Berardinis E, Raimondi C. *The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC)*. *J Cancer Res Clin Oncol*. 2017 Oct;143(10):1971-1976. PMID: 28555356 IF 3.3
20. Nicolazzo C, Raimondi C, Francescangeli F, Ceccarelli S, Trenta P, Magri V, Marchese C, Zeuner A, Gradilone A, **Gazzaniga P** *EpCAM-expressing circulating tumor cells in colorectal cancer*. *Int J Biol Markers*. 2017 Oct 31;32(4) PMID: 28604994 IF 1.5
21. Nicolazzo C, Raimondi C, Loreni F, **Gazzaniga P**, Gradilone A. *Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy*. *Int J Mol Sci*. 2017 Jun 19;18(6). pii: E1308. doi: 10.3390/ijms18061308. PMID: 28629196 IF 4
22. Raimondi C, Carpino G, Nicolazzo C, Gradilone A, Gianni W, Gaudio E, Cortesi E and **Gazzaniga P**. *PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: a molecular shield to evade immune system?* *Oncoimmunology*, 2017 Apr 20;6(12):e1315488. doi: 10.1080/2162402X.2017.1315488. PMID: 29209560 IF 5.5
23. Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, Gandini O, Mastromartino M, Del Bene G, Prete A, Longo F, Cortesi E, **Gazzaniga P**. *Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab*. *Sci Rep*. 2016 Aug 24;6:31726. doi: 10.1038/srep31726 PMID: 27553175 IF 4.2
24. Nicolazzo C, Massimi I, Lotti LV, Vespa S, Raimondi C, Pulcinelli FM, Gradilone A, **Gazzaniga P**. *Impact of chronic exposure to bevacizumab on EpCAM-based detection of circulating tumor cells*. *Chin J Cancer Res*. 2015 Oct;27(5):491-6. PMID: 26543336 IF 2
25. **Gazzaniga P**, Raimondi C, Nicolazzo C, Carletti R, di Gioia C, Gradilone A, Cortesi E. *The rationale for liquid biopsy in colorectal cancer: a focus on circulating tumor cells*. *Expert Rev Mol Diagn*. 2015;15(7):925-32 PMID: 25959553 IF 3.3
26. Raimondi C, Nicolazzo C, Gradilone A, Giannini G, De Falco E, Chimenti I, Varriale E, Hauch S, Plappert L, Cortesi E, **Gazzaniga P**. *Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer*. *Cancer Biol Ther*;15(5):496-503, 2014. PMID: 24521660 IF 3
27. **Gazzaniga P**, de Berardinis E, Raimondi C, Gradilone A, Busetto GM, De Falco E, Nicolazzo C, Giovannone R, Gentile V, Cortesi E, Pantel K. *Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer*. *Int J Cancer*. 2014. Oct 15;135(8):1978-82, PMID: 24599551 IF 5
28. Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, **Gazzaniga P**, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S. *Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data*. *Lancet Oncol*. 2014. Apr;15(4):406-14. PMID: 24636208 IF 24.7
29. Raimondi C, Gradilone A, **Gazzaniga P**. *Circulating tumor cells in early bladder cancer: insight into micrometastatic disease*. *Expert Rev Mol Diagn*. 2014 May;14(4):407-9. PMID: 24717055 IF 3.5
30. Raimondi C, Gradilone A, Naso G, Cortesi E, **Gazzaniga P**. *Clinical utility of circulating tumor cell counting through CellSearch®: the dilemma of a concept suspended in Limbo*. *Onco Targets Ther*. 2014 Apr 17;7:619-625 PMID: 24790460 IF 2.3
31. Raimondi C, Gradilone A, **Gazzaniga P**. *Controversies in circulating tumor cell count during therapy*. *Expert Rev Mol Diagn*. 2013 Jun;13(5):499-507 PMID: 23782256 IF 4.2

32. **Gazzaniga P**, Raimondi C, Gradilone A, Biondi Zoccai G, Nicolazzo C, Gandini O, Longo F, Tomao S, Lo Russo G, Seminara P, Vincenzi B, Chimenti I, Cristofanilli M, Frati L, Cortesi E. *Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?* J Cancer Res Clin Oncol. 2013.139(8):1411-6 PMID: 23736274 IF 3
33. **Gazzaniga P**, Gianni W, Raimondi C, Gradilone A, Lo Russo G, Longo F, Gandini O, Tomao S, Frati L *Circulating tumor cells in high-risk nonmetastatic colorectal cancer*. Tumour Biol. 2013; 34(5):2507-9, PMID: 23539436 IF 2.8
34. Gradilone A, **Gazzaniga P**, Ribuffo D, Bottoni U, Frati L, Agliano', AM, Sorvillo V, Piperno A, Scuderi N, Cigna E *.Prognostic significance of tyrosinase expression in sentinel lymph node biopsy for ultra-thin, thin, and thick melanomas*. Eur Rev Med Pharmacol Sci. 2012 16(10):1367-76 PMID: 23104653 IF 1
35. Cigna E, Gradilone A, Ribuffo D, **Gazzaniga P**, Fino P, Sorvillo V, Scuderi N. *Morbidity of selective lymph node biopsy for melanoma: meta-analysis of complications*. Tumori 2012. Jan-Feb;98(1):94-8, PMID: 22495708 IF 1
36. **Gazzaniga P**, Gianni W, Gradilone A, Raimondi C, Cortesi E, Frati L. *Circulating Tumor Cells In Young And Elderly Patients With Colorectal Cancer: "Lupus Et Agnus"* Aging Clin Exp Res.24(6):722-3, 2012. PMID: 22828412 IF 1
37. **Gazzaniga P**, Gradilone A, de Berardinis E, Busetto GM, Raimondi C, Gandini O, Nicolazzo C, Petracca A, Vincenzi B, Farcomeni A, Gentile V, Cortesi E, Frati L. *Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis*. Ann Oncol.23(9):2352-6,2012. PMID: 22351740 IF 7.3
38. Iacovelli R.,Palazzo A.,Procopio G.,**Gazzaniga P**.,Cortesi E. *Abiraterone acetate in castration-resistant prostate cancer* Anti-Cancer Drugs Volume 23, Issue 3, Pages 247 – 254 March 2012 DOI10.1097/CAD.0b013e32834e696c IF 2.5
39. **Gazzaniga P**, Raimondi C, Gradilone A, Naso G, Cortesi E, Frati L. *Circulating tumor cells: highlight on practical implications*. Mol Diagn Ther. Feb 1;16(1):7-11,2012 PMID: 22303967 IF 2
40. Gradilone A, Iacovelli R, Cortesi E, Raimondi C, Gianni W, Nicolazzo C, Petracca A, Palazzo A, Longo F, Frati L, **Gazzaniga P**. *Circulating tumor cells and "suspicious objects" evaluated through CellSearch® in metastatic renal cell carcinoma*. Anticancer Res. Dec;31(12):4219-21, 2011. PMID: 22199284 IF 2
41. Gradilone A, Raimondi C, Naso G, Silvestri I, Repetto L, Palazzo A, Gianni W, Frati L, Cortesi E, **Gazzaniga P**. *How circulating tumor cells escape from multidrug resistance: translating molecular mechanisms in metastatic breast cancer treatment*. Am J Clin Oncol. Dec;34(6):625-7, 2011 PMID: 22101388 IF 2
42. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F, Cortesi E, **Gazzaniga P**. *Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients*. Breast Cancer Res Treat. Nov;130(2):449-55, 2011 PMID: 21298334 IF 4.9
43. **Gazzaniga P**, Naso G, Raimondi C, Gradilone A, Palazzo A, Gandini O, Petracca A, Nicolazzo C, Cortesi E, Frati L. *Circulating tumor cells count and characterization in a male breast cancer patient*. Cancer Biol Ther. Sep 1;12(5):379-82, 2011 PMID: 21725206 IF 2.6
44. **Gazzaniga P**, Raimondi C, Gradilone A, Di Seri M, Longo F, Cortesi E, Frati L. *Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero*. Ann Oncol. Aug;22(8):1929-30, 2011 PMID: 21633048 IF 6.4
45. Mattiello T, Guerriero R, Lotti LV, Trifirò E, Felli MP, Barbarulo A, Pucci B, **Gazzaniga P**, Gaudio C, Frati L, Pulcinelli FM. *Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting*. J Am Coll Cardiol. Aug 9;58(7):752-61, 2011. Erratum in: J Am Coll Cardiol. Oct 18;58(17):1832, 2011 PMID: 21816313 IF 14
46. A. Gradilone, G. Naso., C. Raimondi, E. Cortesi, O. Gandini, B. Vincenzi , R. Saltarelli, E. Chiapparino, F. Spremberg, M. Cristofanilli, L. Frati , A.M. Aglianò, and **P. Gazzaniga**. *Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): Prognosis, drug resistance and phenotypic characterization*. Annals Oncol, Jan;22(1):86-92, 2011 PMID: 20603432 IF 6.4

47. Gradilone A, **Gazzaniga P**, Raimondi C, Aglianò AM, Frati L. *Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties*. *Int J Cancer*. Apr 15;128(8):1997-8, 2011 PMID: 20568108 IF 5.4
48. Gradilone A, Raimondi C, Nicolazzo C, Petracca A, Gandini O, Vincenzi B, Naso G, Aglianò AM, Cortesi E, **Gazzaniga P**. *Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal*. *J Cell Mol Med*. May;15(5):1066-70, 2011 PMID: 21352474 IF 4
49. **Gazzaniga P**, Cigna E, Panasiti V, Devirgiliis V, Bottoni U, Vincenzi B, Nicolazzo C, Petracca A, Gradilone A. *CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients*. *Eur J Surg Oncol*. Dec;36(12):1211-4, 2010 PMID: 20573479
50. **P. Gazzaniga**, A. Gradilone, A. Petracca, C. Nicolazzo, C. Raimondi, R. Iacovelli, G. Naso, E. Cortesi. *Molecular markers in circulating tumor cells from metastatic colorectal cancer patients* *J Cell Mol Med*. Aug;14(8):2073-7, 2010 PMID: 20597995 IF 4.6
51. Raimondi C, Naso G, Gradilone A, Gianni W, Cortesi E, **Gazzaniga P**. *Circulating Tumor Cells in Cancer Therapy: Are we Off Target?* *Curr Cancer Drug Targets*. Aug;10(5):509-18, 2010 PMID: 20384574 IF 4.8
52. Raimondi C, Cortesi E, Gianni W, **Gazzaniga P**. *Cancer Stem Cells and Epithelial-Mesenchymal Transition: Revisiting Minimal Residual Disease*. *Curr Cancer Drug Targets*. Aug;10(5):496-508, 2010 PMID: 20384575 IF 4.8
53. **Gazzaniga P (guest editor)**. *Cancer Therapy: Are we Missing the Target?* *Curr Cancer Drug Targets*. Aug;10(5):432, 2010 IF 4.8
54. Gradilone A, Petracca A, Nicolazzo C, Gianni W, Cortesi E, Naso G, Vincenzi B, Cristini C, de Berardinis E, di Silverio F, Aglianò AM, **Gazzaniga P**. *Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer*. *BJU Int*. 106(5):710-5, 2010 PMID: 20128783 IF 3.2
55. **Gazzaniga P**, Naso G, Gradilone A, Cortesi E, Gandini O, Gianni W, Fabbri MA, Vincenzi B, di Silverio F, Frati L, Aglianò AM, Cristofanilli M. *Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors*. *Int J Cancer*. May 15;126(10):2437-47, 2010 PMID: 19821489 IF 4.9
56. **Paola Gazzaniga**, Angela Gradilone, Ettore de Berardinis, Alessandro Sciarra, Cristiano Cristini, Giuseppe Naso, Franco di Silverio, Luigi Frati, Anna Maria Aglianò. *A chemosensitivity test to individualize intravesical treatment in non muscle invasive bladder cancer*. *BJU Int*. 104(2):184-8, 2009 PMID: 19154503 IF 2.8
57. Gianni W., **Gazzaniga P.**, Zuccaro S., Giuseppe Luzi *Don't worry, Your Holiness!* *BMJ*;338:b39, doi: 10.1136/bmj.b39, 2009 PMID: 19136541 IF 12
58. **Gazzaniga P**, Cigna E, Vincenzi B, Bottoni U, Vasaturo F, Alfano C, Calvieri S, Frati L, Scuderi N, Aglianò AM, Gradilone A. *Tenascin C: A defensive role in sentinel lymph nodes of melanoma patients?* *J Dermatol Sci*. Mar;53(3):239-41, 2008 PMID: 19070467 IF 3
59. A. Gradilone, A. Spadaro, W. Gianni. A. M. Aglianò, and **P. Gazzaniga**. *Induction of multidrug resistance proteins in lymphocytes from patients with arthritic disorders*. *Clinical and Experimental Medicine*., Dec;8(4):229-30, 2008 PMID: 18815867 IF 2
60. A. Gradilone, F. M. Pulcinelli, L. V. Lotti, E. Trifirò, S. Martino, O. Gandini, W. Gianni, L. Frati, A. M. Aglianò, and **P. Gazzaniga**. *Celecoxib upregulates Multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy*. *Current Cancer Drugs Targets*, Aug;8(5):414-20, 2008 PMID: 18690847 IF 4.3
61. **Gazzaniga P.**, Gradilone A., Naso G., Cortesi E., Gianni W., Frati L., Aglianò A. M. *Chemoresistance profile of circulating tumor cells: toward a clinical benefit?* *Int. J. Cancer*, Oct 1;123(7):1730-2, 2008 PMID: 18646187 IF 4.7
62. **Gazzaniga P.**, Silvestri I., Gradilone A., Aglianò A.M. *The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy*. *BJU Int*. Jan;101(1):127, 2008 PMID: 18086103 IF 2.8
63. Gradilone A., Pulcinelli F.M.i, Lotti L.V., Martino S., Mattiello T., Frati L., Aglianò A.M., **Gazzaniga P**. *Celecoxib induces MRP 4 in lung cancer cells: therapeutic implications*. *J. Clin. Oncol*. Sep 20;25(27):4318-20, 2007 PMID: 17878487 IF 15.4

64. Stigliano A., Gandini O., Cerquetti L., **Gazzaniga P.**, Misiti S., Monti S., Gradilone A., Falasca P., Poggi M., Brunetti E., Aglianò A. M. and Toscano V. *Increased MLN64 and CYP17 expression are associated with high staged prostate cancer.* J. Endocr. Jul;194(1):55-61, 2007 PMID: 17592021 IF 2.6
65. A. Gradilone, **P. Gazzaniga**, E. Cigna, F. Vasaturo, B. Vincenzi, O. Gandini, I. Silvestri, D. Ribuffo, S. Scarpa, N. Scuderi, AM Aglianò. *Fibronectin and laminin expression in sentinel lymph nodes of melanoma patients.* Br. J. Dermatol. Aug;157(2):398-401, 2007 PMID: 17573891 IF 3.5
66. Gradilone A., Silvestri I., Scarpa S., Morrone S., Gandini O., Pulcinelli F. M., Gianni W., Aglianò A.M., **Gazzaniga P.** *Failure of apoptosis and activation of NFkB by celecoxib and aspirin in lung cancer cell lines.* Oncol. Rep. Apr;17(4):823-8, 2007 PMID: 17342322 IF 1.6
67. **Gazzaniga P.**, Silvestri I., Gradilone A., Scarpa S., Morrone S., Gandini O., Gianni W., Frati L., Aglianò A. M. *Gemcitabine induced apoptosis in 5637 cell line: an in vitro model for superficial bladder cancer.* Anticancer Drugs. Feb;18(2):179-85, 2007 PMID: 17159604 IF 1.5
68. **Gazzaniga P.**, Nofroni I., Gandini O., Silvestri I., Frati L., Aglianò A. M., Gradilone A. *Tenascin c and epidermal growth factor receptor as markers of circulating tumor cells in bladder and colon cancer.* Oncol Rep. Nov;14(5):1199-202, 2005 PMID: 16211285 IF 1.6
69. Repetto L., Gianni W., Aglianò A.M. and **Gazzaniga P.** *Impact of EGFR expression on colorectal cancer patients prognosis and survival: a response.* Ann. Oncol, Sep;16(9):1557, 2005 PMID: 15871994 IF 4.3
70. Gradilone A., Ribuffo D., Silvestri I., Cigna E., **Gazzaniga P.**, Nofroni I., Zamolo G., Frati L., Scuderi N., Aglianò A.M. *Detection of melanoma cells in sentinel lymph nodes by reverse transcriptase polymerase chain reaction: prognostic significance.* Annals of Surg. Oncol., Nov. 11 (11) . 983-7, 2004 PMID: 15525827 IF 4
71. Gianni W., Ricci A., **Gazzaniga P.**, Brama M., Pietropaolo M., Votano S., Patanè F., Aglianò A. M, Spera G., Marigliano V., Ammendola S., Agnusdei D., Migliaccio S. and Scandurra R *Raloxifene modulates IL-6 and TNF alpha synthesis in vivo: results from a pilot clinical study.* J. Clin Endocrinol. and Metab, Dec, 89 (12): 6097-9, 2004 PMID: 15579764 IF 6
72. Messina E., **Gazzaniga P.**, Micheli V., Barile L., Lupi F., Aglianò A. M., Giacomello A. *Low levels of mycophenolic acid induce differentiation of human neuroblastoma cell lines.* Int. J. Cancer, Nov 1; 112 (2): 352-354, 2004 PMID: 15352052 IF 4.4
73. Gradilone A., **Gazzaniga P.**, Ribuffo D., Scarpa S., Cigna E., Vasaturo F., Bottoni U., Innocenzi D., Calvieri S., Scuderi N., Frati L., Aglianò A. M. In reply. J. Clin Oncol. 22 (13) 2752, 2004 IF 9.8
74. E. Messina, **P. Gazzaniga**, V. Micheli, M. G. Guaglianone, S. Barbato, S. Morrone, L. Frati, A. M. Aglianò, A. Giacomello. *Guanine nucleotide depletion triggers cell cycle arrest and apoptosis in human neuroblastoma cell lines.* Int. J. Cancer, Mar 1; 108(6): 812-7, 2004 PMID: 15352052 IF 4.4
75. L. Giacomelli, W. Gianni, C. Belfiore, O. Gandini, L. Repetto, A. Filippini, L. Frati, A.M. Aglianò and **P. Gazzaniga.** *Persistence of EGFR and IL-10 in blood of colorectal cancer patients after surgery identifies patients with high risk to relapse.* Clin Cancer Res, 2678-2682, 2003 PMID: 12855647 IF 6.5
76. Gradilone A., **Gazzaniga P.**, Ribuffo D., Scarpa S., Cigna E., Vasaturo F., Bottoni U., Innocenzi D., Calvieri S., Scuderi A., Frati L., Aglianò A. M. *Survivin, bcl-2, bax and bcl-x gene expression in lymph node metastases from melanoma patients evaluated by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR).* J Clin Oncol, Jan 15;21(2):306-12, 2003 PMID: 12525523 IF 10.8
77. **Gazzaniga P.**, Gradilone A., Giuliani L., Gandini O., Silvestri I., Nofroni I., Saccani G., Frati L, Aglianò A. M. *Expression and prognostic significance of livin, survivin and other apoptosis related genes in the progression of superficial bladder cancer.* Annals Oncol., 2003 Jan;14(1):85-90 PMID: 12488298 IF 3.6
78. A. Gradilone, **P. Gazzaniga**, I. Silvestri, O. Gandini, L. Trasatti, S. Lauro, L. Frati, AM Aglianò. *Detection of CK-19, CK-20 and EGFR mRNAs in peripheral blood of carcinoma patients: correlation with clinical stage of disease.* Oncol. Rep., 10 (1): 217-222, 2003 PMID: 12469172 IF 1.2



79. **Gazzaniga P.**, Gradilone A., Frati L. and Agliano A.M. *Epidermal growth factor receptor (EGFR) mRNA expression in peripheral blood of bladder cancer patients: a potential marker to detect treatment failure*. Clin Cancer Res, 7(12):4288-9, 2001 PMID: 11751531 IF5
80. Magnanti M., Gandini O., Giuliani L., **Gazzaniga P.**, Marti H. H., Gradilone A., Frati L., Agliano A. M., and Gassmann M. *Erythropoietin expression in primary rat Sertoli and peritubular myoid cells*. Blood 98(9): 2872-4, 2001 PMID: 11675366 IF 9.2
81. Girasole M., Cricenti A., Generosi R., Silvestri I., **Gazzaniga P.**, Pozzi D., Agliano' A.M. *Atomic force microscopy detect transient frictional contrasts in apoptotic cells induced by deprivation of interleukin-3*. Appl. Phys. Letters, 78 (8) 1143-1145, 2001 <https://doi.org/10.1063/1.1350976> IF 3.5
82. **Gazzaniga P.**, Gandini O., Giuliani L., Magnanti M., Gradilone A., Silvestri I., Gianni W., Gallucci M., Frati L. and Agliano' A. M. *Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients*. Clin. Cancer Res., 7; 577-583, 2001 PMID: 11297251 IF 5
83. Giuliani L, **Gazzaniga P.**, Caporuscio F, Ciotti M, Frati L, Agliano AM. *Can down-regulation of UDP-glucuronosyltransferases in the urinary bladder tissue impact the risk of chemical carcinogenesis?* Int J Cancer. 2001 Jan 1;91(1):141-3. doi: 10.1002/1097-0215(20010101)91:1<141::aid-ijc1005>3.0.co;2-h. PMID: 11149414. IF 4.2
84. Magnanti M., Giuliani L., Gandini O., **Gazzaniga P.**, Santiemma V., Ciotti M., Saccani G., Frati L., Agliano' A. M. *Follicle-stimulating hormone, testosterone, and hypoxia differentially regulate UDP-glucuronosyl-transferase 1 isoforms expression in rat Sertoli and peritubular myoid cells*. J. Steroid Biochem Mol Biol, 74, 3-4, 2000 PMID: 11086234 IF 2.2
85. Agliano' A. M., Castiglia R., Santangelo C., Silvestri I., **Gazzaniga P.**, Giuliani L., Naso G., Frati L. *On chromosomal instability: what is the karyotype of your 32D cell line?* Blood, June 1, 95 (11): 3636-7, 2000 PMID: 10877550 IF 9
86. Gandini O., Celi F. S., Magnanti M., **Gazzaniga P.**, Silvestri I., Conti B., Giuliani L., Mentuccia D., Agliano A. M.. *Rapid, simple inexpensive step facilitates RNA extraction from whole blood cells*. Lab. Investigation Dec. 79 (12): 1731-1732, 1999 PMID: 10616222 IF 4.5
87. **Gazzaniga P.**, Gandini O., Gradilone A., Silvestri I., Giuliani L., Magnanti M., Gallucci M., Saccani G., Frati L., Agliano' A. M. *Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: correlation with local relapses*. Int. J. Oncology, June 14(6) 1123-1127, 1999 PMID: 10339668 IF1.3
88. **Gazzaniga P.** and A. M. Agliano'. In reply .Cancer Letters 1999 Apr. 1; 137 (2): 227-229 PMID: 10374845 IF 1.5
89. **Gazzaniga P.**, Vercillo R., Gradilone A., Silvestri I., Gandini O., Napolitano M., Giuliani L., Fioravanti A., Gallucci M., Agliano' A. M. *Prevalence of Papillomavirus, Epstein-Barr virus, Cytomegalovirus and Herpes Simplex virus type 2 in urinary bladder cancer*. J. Med. Virol., Aug. 55(4): 262-267, 1998 PMID: 9661833 IF 2.5
90. **Gazzaniga P.**, Gradilone A., Silvestri I., Gandini O., Giuliani L., Vincenzoni A., Gallucci M., Frati L., Agliano' A.M. *Variable levels of bcl-2, bcl-X and bax mRNA in bladder cancer progression*. Oncology Reports, Jul 5(4): 901-904, 1998 PMID: 9625842 IF 1
91. **Gazzaniga P.**, Gradilone A., Silvestri I, Gandini O., Napolitano M., Vercillo R., Vincenzoni A., Gallucci M., Frati L., Agliano' A.M. *High levels of TGF-alpha mRNA may predict local relapses in low stage urinary bladder cancer*. Eur. J. Cancer, Vol 34, 6: 934-936, 1998 PMID: 9797711 IF 2.7
92. Agliano A.M., Naso G., Silvestri I., Gradilone A., Vercillo R., Napolitano M., **Gazzaniga P.**, Gandini O., Realacci M., Santangelo C., Saccani G., Manzari V. and Frati L. *Involvement of bcl-2 and bax gene expression in apoptosis and differentiation of the non-tumorigenic murine hematopoietic cell line, 32DC13(G)*. Int. J. Oncology 11, 1271-1277, 1997 PMID: 21528334 IF 1
93. Gianni W., De Vincentis G., Ierardi M., Fimognari F.L., Banci M., **Gazzaniga P.**, Cacciafesta M., Di Tondo U., Scopinaro F., Marigliano V. *Scintigraphic imaging of hepatic epithelioid hemangioendothelioma*. Digestion 58: 498-500, 1997 PMID: 9383644 IF 1.3

94. Gradilone A., Vercillo R., Napolitano M., Cardinali G., **Gazzaniga P.**, Silvestri I., Gandini O., Tomao S. and Aglianò A.M. *Prevalence of human Papillomavirus, Cytomegalovirus and Epstein-Barr virus in the cervix of healthy women.* J. Med. Virol. Sep 50: 1-4, 1996 PMID: 8890032 IF 4
95. **Gazzaniga P.**, Gradilone A., Vercillo R., Gandini O., Silvestri I., Napolitano M., Albonici L., Vincenzoni A., Gallucci M., Frati L. Aglianò A. M. *bcl 2/bax mRNA expression ratio as prognostic factor in low grade urinary bladder cancer.* Int. J. Cancer Apr. 22 69(2):100-104, 1996 PMID: 8608975 IF 3.4
96. Gradilone A., Greco C., **Gazzaniga P.**, Vercillo R., Napolitano M., Gandini O., Mattei F., Frati L., Aglianò A. M. *Bax gene expression in melanoma metastases.* Journal of Investigative Dermatology 106, 382, 1996 PMID: 8601748 IF 4.5
97. Gianni W., Vetta F., Lato P.F.A., Bucher L., **Gazzaniga P.**, Bressan A.M., Birarelli P., Di Massimo M., Cacciafesta M., Piccoli M., Marigliano V. *Low NK activity as unfavourable prognostic marker in elderly patients with cancer.* Journal of Tumor Marker Oncology Volume 11, Issue 2, Pages 161 – 163, 1996 IF 1
98. **Gazzaniga P.**, Gallucci., Gradilone A., Gandini O., Vincenzoni A., Gianni W., Naso G., Frati L., Aglianò A. M. *Detection of bcl-2 RNA in low grade tumours of the urinary bladder.* Eur. J. Cancer 31A, 12, 2219-2120, 1995 PMID: 8562180 IF 2.4
99. Aglianò A. M., Gradilone A., **Gazzaniga P.**, Napolitano M., Vercillo R., Albonici L., Naso G., Manzari V., Frati L., Vecchione A. *High frequency of human papillomavirus detection in urinary bladder cancer.* Urol. Int. 53, 125-129, 1994 PMID: 7645137 IF 1
100. Aglianò A. M., **Gazzaniga P.**, Cervigni M., Gradilone A., Napolitano M., Pastore L. I., Manzari V., Frati L., Vecchione A. *Detection of human papillomavirus type 16 DNA sequences in paraffin-embedded tissues from the female urinary tract.* Urol. Int. 52, 208-212, 1994 PMID: 8030168 IF 1

#### Books chapters

- 1) **P. Gazzaniga** Muerte celular programada en el cancer vesical. Cap. 19, pag. 159-164 In : Cancer de vejica, Schering Espana, 2004
- 2) Gandini O., Kohno H, **P. Gazzaniga**, Korach K. Alteration Of Transcriptional Activity Of The Mouse Estrogen Receptor By N-Terminal Deletions And C-Terminal Point Mutations. In: De Bellis A. And Schipani E. "Future Trends In Endocrinology". Vol. 1, De Bellis A. And Schipani E, Isbn/Issn: 9788885974432, 1995

Roma, 26/10/2021

